key: cord-0759681-7n6pva1l
authors: Seow, J.; Graham, C.; Merrick, B.; Acors, S.; Steel, K. J. A.; Hemmings, O.; O'Bryne, A.; Kouphou, N.; Pickering, S.; Galao, R.; Betancor, G.; Wilson, H. D.; Signell, A. W.; Winstone, H.; Kerridge, C.; Temperton, N.; Snell, L.; Bisnauthsing, K.; Moore, A.; Green, A.; Martinez, L.; Stokes, B.; Honey, J.; Izquierdo-Barras, A.; Arbane, G.; Patel, A.; OConnell, L.; O Hara, G.; MacMahon, E.; Douthwaite, S.; Nebbia, G.; Batra, R.; Martinez-Nunez, R.; Edgeworth, J. D.; Neil, S. J. D.; Malim, M. H.; Doores, K.
title: Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection
date: 2020-07-11
journal: nan
DOI: 10.1101/2020.07.09.20148429
sha: 22105aeedc5163b9b8376cd3d2778763b16536ac
doc_id: 759681
cord_uid: 7n6pva1l

Antibody (Ab) responses to SARS-CoV-2 can be detected in most infected individuals 10-15 days following the onset of COVID-19 symptoms. However, due to the recent emergence of this virus in the human population it is not yet known how long these Ab responses will be maintained or whether they will provide protection from re-infection. Using sequential serum samples collected up to 94 days post onset of symptoms (POS) from 65 RT-qPCR confirmed SARS-CoV-2-infected individuals, we show seroconversion in >95% of cases and neutralizing antibody (nAb) responses when sampled beyond 8 days POS. We demonstrate that the magnitude of the nAb response is dependent upon the disease severity, but this does not affect the kinetics of the nAb response. Declining nAb titres were observed during the follow up period. Whilst some individuals with high peak ID50 (>10,000) maintained titres >1,000 at >60 days POS, some with lower peak ID50 had titres approaching baseline within the follow up period. A similar decline in nAb titres was also observed in a cohort of seropositive healthcare workers from Guy's and St Thomas' Hospitals. We suggest that this transient nAb response is a feature shared by both a SARS-CoV-2 infection that causes low disease severity and the circulating seasonal coronaviruses that are associated with common colds. This study has important implications when considering widespread serological testing, Ab protection against re-infection with SARS-CoV-2 and the durability of vaccine protection.

Antibody (Ab) responses to SARS-CoV-2 can be detected in most infected individuals 10-15 29 days following the onset of COVID-19 symptoms. However, due to the recent emergence of 30 this virus in the human population it is not yet known how long these Ab responses will be 31 maintained or whether they will provide protection from re-infection. Using sequential serum 32 samples collected up to 94 days post onset of symptoms (POS) from 65 RT-qPCR confirmed 33 SARS-CoV-2-infected individuals, we show seroconversion in >95% of cases and neutralizing 34 antibody (nAb) responses when sampled beyond 8 days POS. We demonstrate that the 35 magnitude of the nAb response is dependent upon the disease severity, but this does not 36 affect the kinetics of the nAb response. Declining nAb titres were observed during the follow 37 up period. Whilst some individuals with high peak ID50 (>10,000) maintained titres >1,000 at 38 >60 days POS, some with lower peak ID50 had titres approaching baseline within the follow 39 up period. A similar decline in nAb titres was also observed in a cohort of seropositive 40 healthcare workers from Guy's and St Thomas' Hospitals. We suggest that this transient nAb 41 response is a feature shared by both a SARS-CoV-2 infection that causes low disease severity 42 and the circulating seasonal coronaviruses that are associated with common colds. This study 43 has important implications when considering widespread serological testing, Ab protection 44 against re-infection with SARS-CoV-2 and the durability of vaccine protection. 45

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a betacoronavirus 47 responsible for coronavirus disease-19 (COVID-19). Spike (S) is the virally encoded surface 48 glycoprotein facilitating angiotensin converting enzyme-2 (ACE-2) receptor binding on target 49 cells through its receptor binding domain (RBD). In a rapidly evolving field, researchers have 50 already shown that, in most cases, individuals with a confirmed PCR diagnosis of SARS-CoV-2 51 infection develop IgM, IgA and IgG against the virally encoded surface spike protein (S) and 52 nucleocapsid protein (N) within 1-2 weeks post onset of symptoms (POS) and remain elevated 53 following initial viral clearance. [1] [2] [3] [4] [5] [6] [7] S is the target for nAbs, and a number of highly potent 54 monoclonal antibodies (mAbs) have been isolated that predominantly target the RBD. 8 Here, we measured the Ab binding response to S, the receptor binding domain (RBD) and N, 78 as well as the neutralization potency against SARS-CoV-2 using an HIV-1 based pseudotype 79 assay. We show that IgM and IgA binding responses decline after 20-30 days POS. We 80 demonstrate that the magnitude of the nAb response is dependent upon the disease severity 81 but this does not impact on the time to ID50 peak (serum dilution that inhibits 50% infection). 82 nAb titres peak on average at day 23 POS and then decrease 2-to 23-fold during an 18-65 day 83 follow up period. In individuals that only develop modest nAb titres following infection (100-84 300 range), titres become undetectable (ID50 <50) or are approaching baseline after ~50 days 85 highlighting the transient nature of the Ab response towards SARS-CoV-2 in some individuals. 86

In contrast, those with high peak ID50 for neutralization maintain nAb titres in the 1000-3500 87 range at the final timepoint tested (>60 days POS). This study has important implications 88 when considering protection against re-infection with SARS-CoV-2 and the durability of 89 vaccine protection. 90 91

Cohort description: 93

The antibody response in 65 RT-qPCR confirmed SARS-CoV-2-infected individuals was studied 94 over sequential time points. The cohort consisted of 59 individuals admitted to, and 6 95 healthcare workers (HCW) at, Guy's and St Thomas' NHS Foundation Trust (GSTFT). The 96 cohort were 77.2% male with average age of 55.2 years (range 23-95 years). Ethnicity 97 information was not collected on this cohort. A severity score was assigned to patients based 98 on the maximal level of respiratory support they required during their period of 99 hospitalisation. The score, ranging from 0-5 (see methods), was devised to mitigate 100 underestimating disease severity in patients not for escalation above level one (ward-based) 101

care. This cohort included the full breadth of COVID-19 severity, from asymptomatic infection 102 to those requiring extra corporeal membrane oxygenation (ECMO) for severe respiratory 103 failure. Comorbidities included diabetes mellitus, hypertension, and obesity, with a full 104 summary in Table S1 . Sequential serum samples were collected from individuals at time-105 points between 1-and 94-days post onset of symptoms (POS) and were based upon 106 availability of discarded samples taken as part of routine clinical care, or as part of a HCW 107 study. 108 109 Antibody binding responses to SARS-CoV-2: 110

The IgG, IgM and IgA response against spike (S), the receptor binding domain (RBD) and 111 nucleocapsid (N) were measured by ELISA over multiple time points (Figure 1 and S1). 6 112 Initially, the optical density at 1:50 serum dilution was measured for 300 samples from the 65 113 individuals (Figure 1 and S1). Only 2/65 individuals (3.1%) did not generate a detectable Ab 114 response against any of the antigens in the follow up period (Table S2) . However, sera were 115 only available up until 2-and 8-days POS for these two individuals and as the mean time to 116 seroconversion against at least 1 antigen was 12.6 days POS, it is likely these individuals may 117 have seroconverted at a later time point after they were discharged from hospital. IgG 118 responses against S, RBD and N antigens were observed in 92.3%, 89.2% and 93.8% of 119 individuals respectively ( IgA response to all three antigens following the peak OD between 20-and 30-days POS for 138

IgM and IgA respectively (Figure 1B and S1A) as might be expected following an acute 139 infection. For some individuals sampled at time points >60 days POS, the IgM and IgA 140 responses were approaching baseline (Figure 2B and S1A). In contrast, the IgG OD (as 141 measured at 1:50 dilution) remained high in the majority of individuals, even up to 94 days 142 POS ( Figure 1B and S1A) . However, differences were apparent when patients were stratified 143 by disease severity and when half maximal binding (EC50) was measured (see below). To determine how disease severity impacts Ab titres, we compared the ID50 values between 165 individuals with 0-3 disease severity with those in the 4/5 group (Figure 3) . Although the 166 magnitude of the nAb response at peak neutralization was significantly higher in the severity 167 4/5 group (Figure 3A) , the time taken to measure detectable nAb titres ( Figure 3C ) and the 168 time of peak neutralization ( Figure 3B ) did not differ between the two groups suggesting 169 disease severity enhances the magnitude of the Ab response but does not alter the kinetics. 170

Comparison of the IgG, IgM and IgA OD values against S at peak neutralization showed 171 significantly higher IgA and IgM ODs in the severity 4/5 group but no significant difference 172 was observed for IgG to S (Figure 3D-F) . This observation may further highlight a potential 173 role for IgA and IgM in neutralization. 19 Within the severity 4/5 group, a proportion of patients 174 were treated with immunomodulation for a persistent hyperinflammatory state 175 characterized by fevers, markedly elevated CRP and ferritin, and multi-organ dysfunction. 176

Despite an initial working hypothesis that antibody responses may differ either as a cause or 177 consequence of this phenotype, no difference in ID50 titres was observed between these 178 individuals and the remainder of the severity 4/5 cases ( Figure 3G) . and symptomatic HCWs showed a very similar mean peak ID50. In contrast, both groups had 219 lower mean ID50 values compared to hospitalized individuals in the 0-3 and 4/5 severity 220 groups ( Figure 5B) . Importantly, some asymptomatic individuals could generate 221 neutralization titres >1,000. Similar to the cohort with confirmed SARS-CoV-2 infection, a 222 decline in ID50 was observed following peak neutralization. For many individuals with a peak 223 ID50 in the 100-500 range, neutralization was approaching baseline after 50 days POS ( Figure  224 5C). As the mean peak ID50 was lower in the HCW cohort, the decline in nAb titres towards 225 baseline was more frequent compared to the patient cohort. 226 227

Here, we describe the Ab responses in sequential samples from multiple individuals following 229 SARS-CoV-2 infection in hospitalized patients and healthcare workers. We show that all PCR+ 230 patients sampled >8 days POS developed nAbs with peak ID50 in the range of 98-32,000. This 231 wide range in nAb titres against SARS-CoV-2 pseudotyped virus has been observed in other 232 cross-sectional cohorts. 4,16 Although the average nAb titre was higher in those with more 233 severe disease, the average time to reach peak neutralization did not differ between the 0-3 234 and 4/5 severity groups. This suggests that disease severity enhances the magnitude of the 235 nAb response but to a lesser extent the kinetics of the nAb response. Importantly, some 236 seropositive individuals who were asymptomatic were able to generate nAb titres >1000. 237

Indeed, highly potent neutralizing monoclonal antibodies (mAbs) have been isolated from 238 asymptomatic patients. 20 severity. This decrease was mirrored in the reduction in IgG binding titres (EC50) to S and RBD 255 for the PCR+ cohort ( Figure 4B ). For some individuals with a peak ID50 in the 100-300 range, 256 neutralizing titres were at, or below, the level of detection in the SARS-CoV-2 pseudotype 257 neutralization assay after only ~50 days from the measured peak of neutralization. This trend 258 was also seen in the HCW cohort, and reveals that in some individuals, SARS-CoV-2 infection 259 generates only a transient Ab response that rapidly declines. For those with peak ID50 titres 260 >2,000, decline in nAb titres ranged from 2-to 23-fold over an 18-65 day period. It is not clear 261 whether this decline will continue on a downward trajectory or whether the IgG level will 262 plateau to a steady state. Although some nAb titres remain in the 1000-3500 range at the were frequent 12 months after an initial infection. 14 Further, individuals experimentally 296 infected with endemic alphacoronavirus 229E, generated high Ab titres after 2 weeks but 297 these rapidly declined in the following 11 weeks and by 1 year, the mean Ab titres had 298 reduced further but they were still higher than before the first virus challenge. 10 Subsequent 299 virus challenge lead to reinfection (as determined by virus shedding) yet individuals showed 300 no cold symptoms. 10 301 302

The nAb titre required for protection from re-infection in humans is not yet understood. 303

Neutralizing monoclonal antibodies (mAbs) isolated from SARS-CoV-2 infected individuals can 304 protect from disease in animal challenge models in a dose dependant manner. 9,28,29 SARS-305

CoV-2 infected rhesus macaques, who developed nAbs titres of ~100 (range 83-197), did not 306

show any clinical signs of illness when challenged 35 days after the first infection. 30 However, 307 virus was still detected in nasal swabs, albeit 5-logs lower than in primary infection, suggesting 308 immunologic control rather and sterilizing immunity. Similarly, a second study showed rhesus 309 macaques with nAb titres between 8-20 had no clinical signs of disease or detectable virus 310 following re-challenge 28 days after primary infection. 31 Therefore, although nAb titres are 311 declining over a 2-3 month period in the two cohorts described here, individuals with high 312 peak ID50s (>2,000) would likely have sufficient nAb titres to be protected from clinical illness 313 for some time if re-exposed to SARS-CoV-2. Table S1 . 

A serological assay to detect SARS-CoV-2 seroconversion in humans

Antibodies to coronaviruses are higher in 533 older compared with younger adults and binding antibodies are more sensitive than 534 neutralizing antibodies in identifying coronavirus-associated illnesses

Antibody responses to SARS-CoV-2 in patients with COVID-19

Serological Analysis of New York City COVID19 Convalescent 539 Plasma Donors. medRxiv

Severe Acute Respiratory Syndrome Coronavirus 2-Specific 541

Antibody Responses in Coronavirus Disease Patients

Comparative assessment of multiple COVID-19 serological 544 technologies supports continued evaluation of point-of-care lateral flow assays in 545 hospital and community healthcare settings

Cross-sectional evaluation of humoral responses against SARS-CoV-2

Potent neutralizing antibodies from COVID-19 patients define 550 multiple targets of vulnerability

Isolation of potent SARS-CoV-2 neutralizing antibodies and 552 protection from disease in a small animal model

The time course of the immune 555 response to experimental coronavirus infection of man

The dynamics of humoral immune responses following SARS-558

CoV-2 infection and the potential for reinfection

Longitudinal profile of antibodies against SARS-coronavirus in SARS 561 patients and their clinical significance

SARS-CoV-2 vaccines: 'Warp Speed' needs mind melds not 564 warped minds

Coronavirus protective immunity is short-lasting. medRxiv

Disappearance of 568 antibodies to SARS-associated coronavirus after recovery

Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered 571 patient cohort and their implications. medRxiv

An optimised method for the production of 574 MERS-CoV spike expressing viral pseudotypes

Neutralising antibodies to SARS coronavirus 2 in Scottish blood 577 donors -a pilot study of the value of serology to determine population exposure

IgA dominates the early neutralizing antibody response to SARS-CoV-580 2. medRxiv

Convergent antibody responses to SARS-CoV-2 in convalescent 582 individuals

The potential danger of suboptimal antibody responses in 584 COVID-19

Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Analysis of a SARS-CoV-2-Infected Individual Reveals Development 590 of Potent Neutralizing Antibodies with Limited Somatic Mutation

Clinical Characteristics of 58 Children With a Pediatric 593

Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2

The receptor binding domain of the viral spike protein is an 596 immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

Comparing SARS-CoV-2 with SARS-CoV and influenza 600 pandemics

A human neutralizing antibody targets the receptor binding site of SARS-602

Potent neutralizing antibodies against SARS-CoV-2 identified by high-604 throughput single-cell sequencing of convalescent patients' B cells

SARS-CoV-2 infection protects against rechallenge in rhesus 607 macaques

Primary exposure to SARS-CoV-2 protects against reinfection in rhesus 609 macaques

Immunogenicity of a DNA vaccine candidate for COVID-19

ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 613 pneumonia in rhesus macaques

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Rapid development of an inactivated vaccine candidate for SARS-CoV-2

Robust T cell immunity in convalescent individuals with asymptomatic 619 or mild COVID-19. medRxiv